M. H. Davidson

发表

Statin trials in progress: Unanswered questions

M. H. Davidson, 2001, Current atherosclerosis reports.

Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects

E. Stein, H. Bays, K. Maki, 2006, Clinical cardiology.

Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

C. Ballantyne, L. DiCarlo, H. Bays, 2013 .

Lipidomics - A Novel Strategy for Probing into Systems Biology Operations: Networking between Glycome, Lipidome, Proteome, and Genome

T. Elton, S. Kotha, Rishi B. Patel, 2011 .

The clinical black, white, and gray lessons.

V. P. Pulipati, M. H. Davidson, 2021, Current opinion in lipidology.

Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia 1–3

V. Fulgoni, K. Maki, S. M. Anderson, 1999 .

Safety and Tolerability of Esterified Phytosterols Administered in Reduced-Fat Spread and Salad Dressing to Healthy Adult Men and Women

S. Robins, J. McNamara, K. Maki, 2001, Journal of the American College of Nutrition.

Clinical trials.

M. H. Davidson, 2018, Current opinion in lipidology.

Clinical study of Repatha: it does not affect patients’ cognitive function and significantly reduce blood lipid and prevent coronary atherosclerosis

Carmela, R. Giugliano, M. Sabatine, 2022 .

Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery

B. Khomtchouk, M. H. Davidson, Patrick Sun, 2022, Expert opinion on drug discovery.

Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia

J. Mckenney, D. Hunninghake, J. Isaacsohn, 2001, Clinical cardiology.

Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent

R. Kleinpell, K. Maki, M. Dicklin, 2000, Expert opinion on investigational drugs.

Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial

D. Orloff, S. Nicholls, K. Maki, 2015, Lipids in Health and Disease.

History of Lipidology

A. Gotto, M. H. Davidson, 2020, Contemporary Cardiology.

Low-Density Lipoprotein Subclass Distribution Pattern and Adiposity-Associated Dyslipidemia in Postmenopausal Women

K. Maki, P. Marx, A. Maki, 2000, Journal of the American College of Nutrition.

Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a Multicenter Dose‐Ranging Study

A. Goldberg, D. Hunninghake, E. Stein, 2001, Journal of clinical pharmacology.

Differential effects of simvastatin and atorvastatin on high‐density lipoprotein cholesterol and apolipoprotein A‐I are consistent across hypercholesterolemic patient subgroups

M. Mercuri, J. Frohlich, R. Scott, 2003, Clinical cardiology.

Cyclooxygenase‐2 inhibition by rofecoxib reverses naturally occurring fever in humans

K. Grasing, B. Gertz, S. Adcock, 1999, Clinical pharmacology and therapeutics.

Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia.

James W. Anderson, L. Blonde, J. Anderson, 2000, The American journal of clinical nutrition.

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.

D. Sprecher, S. Schwartz, H. Haber, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Maintenance of lower proportions of (n - 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids.

T. E. Prewitt, W. Lands, P. Bowen, 1992, Biochimica et biophysica acta.

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.

J. Crouse, D. Hunninghake, M. Elam, 1998, Arteriosclerosis, thrombosis, and vascular biology.

The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients.

A. Goldberg, J. Kane, T. A. Hughes, 1995, Atherosclerosis.

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.

J. Isaacsohn, B. Gordon, S. Weiss, 1999, Archives of internal medicine.

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

J. Isaacsohn, R. Goldstein, V. Miller, 1996, JAMA.

Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial.

E. Schaefer, K. Maki, M. Davidson, 1997, Journal of the American College of Nutrition.

Long-term blood cholesterol-lowering effects of a dietary fiber supplement.

H. Superko, D. Edelman, W. Insull, 1999, American journal of preventive medicine.

Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.

K. Maki, M. Davidson, J. Arce, 2000, Archives of internal medicine.

Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals.

S. Schwartz, H. Haber, S. Weiss, 1997, The American journal of cardiology.

A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.

M. Mercuri, D. Hunninghake, D. Illingworth, 2001, Current medical research and opinion.

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.

D R Illingworth, D. Hunninghake, D. Illingworth, 1997, The American journal of cardiology.

A Randomized Multicenter Trial Comparing the Efficacy of Simvastatin and Fluvastatin

D. Hunninghake, D. Illingworth, E. Stein, 1996, Journal of cardiovascular pharmacology and therapeutics.